ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients

Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events in patients receiving PCI compared against aspirin monotherapy (ASA).

ACC 2021 | HOST-EXAM: Clopidogrel vs AAS como monoterapia post DAPT en las angioplastias

This information was provided by the Korean HOST-EXAM study, presented at ACC 2021 scientific sessions, and simultaneously published in the Lancet.

Researchers followed patients for 2 years and observed consistent results across subgroups, regardless baseline and angiographic characteristics. 

Primary end point, a combination of all cause death, MI, stroke, BARC 3 bleeding or higher, at 24 months, occurred in 5.7% of patients randomized to clopidogrel vs 7.7% of patients randomized to ASA (HR 0.73; IC 95% 0.59 a 0.90).

According to authors, the benefits of clopidogrel were observed both in thrombotic and bleeding terms. However, a longer followup in other populations is necessary (the whole cohort was Korean) to be able to reach more definitive conclusions. 

Guidelines on both sides of the Atlantic recommend ASA at long term after coronary PCI, but these study outcomes challenge ASA.


Read also: ACC 2021 | RAPID-TnT: Usefulness of High-Sensitivity Ultra-Fast Troponin T.


The HOST-EXAM randomized 5530 patients from 37 centers in Korea. All patients were free of events (thrombotic or bleeding) were within 6 to 18 months after coronary PCI and had completed the indicated DAPT period.

At the moment of intervention, over half of patients presented stable angina, 19.4% non-STEMI and 17.2% STEMI.

These new and provocative data raise our expectations for longer followup and similar results across different populations. 

HOST-EXAM

Original Title: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.

Reference: Bon-Kwon Koo et al. Presentado en el congreso de la ACC 2021 y publicado simultáneamente en Lancet. https://doi.org/10.1016/S0140-6736(21)01063-1.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...